

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/id/eprint/109039/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Stull, D. E., Griffiths, C. E. M., Gilloteau, I., Zhao, Y., Guana, A., Finlay, Andrew , Sherif, B., Houghton, K. and Puig, L. 2018. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. *British Journal of Dermatology* 178 (6) , pp. 1297-1307. 10.1111/bjd.16366

Publishers page: <http://dx.doi.org/10.1111/bjd.16366>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See <http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



30th June 2017 AYF comments

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Donald E. Stull,¹ Christopher E.M. Griffiths,² Isabelle Gilloteau,³
Yang Zhao,⁴ Adriana Guana,⁵ Andrew Y. Finlay,⁶ Bintu Sherif,⁷
Katherine Houghton,⁸ Luis Puig⁹

¹ RTI Health Solutions, Research Triangle Park, NC, United States; Phone: +1-919-597-5158; E-mail: dstull@rti.org

² Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, The Dermatology Centre, Barnes Building, Salford Royal NHS Foundation Trust, Manchester, United Kingdom M6 8HD; Phone: +44-161-206-4392; E-mail: Christopher.Griffiths@manchester.ac.uk

³ Novartis Pharma AG, Basel, Switzerland; Phone: +41-79-673-97-67; E-mail: isabelle.gilloteau@novartis.com

⁴ Sun Pharma, Cranbury, NJ, United States; Phone: +1 609-720-8132; E-mail: yang.zhao@sunpharma.com

⁵ Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; Phone: +1-862-926-8115; E-mail: Adriana.guana@novartis .com

⁶ Department of Dermatology, Cardiff University School of Medicine, Cardiff, United Kingdom. Phone: +44-29207-42884; E-mail: finlayay@cardiff.ac.uk

⁷ RTI Health Solutions, Research Triangle Park, NC, United States; Phone: +1-919-541-6032; E-mail: bsherif@rti.org

⁸ RTI Health Solutions, Research Triangle Park, NC, United States; Phone: +1-919-485-7721; E-mail: khoughton@rti.org@rti.org

⁹ *Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Mas Casanovas 90, Block A, 5th floor, Module 3, 08041, Barcelona, Spain; Phone +34-935537007; E-mail: LPuig@santpau.cat*

Corresponding Author: Donald E. Stull, PhD; Head, Data Analytics and Design Strategy; RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, 27709, USA; Phone: +1 919.597.5158; E-mail: dstull@rti.org

Source(s) of Support: Novartis Pharma AG, Basel, Switzerland supported this study.

Running Head: Structural equation model of differential effects of secukinumab vs ustekinumab

Word Count: 3,264

Number of Tables and Figures: 1 Table; 6 Figures

What's already known about this topic?

There are only weak to moderate correlations between Psoriasis Area and Severity Index (PASI) and Dermatology life Quality Index (DLQI) scores.

Factors other than area and severity may play a role in patients' evaluations of their health-related quality of life (HRQOL).

Patients perceive pain, itching, and scaling to be the most troubling aspects of their psoriasis.

What does this study add?

Both PASI response and improved psoriasis-related symptoms of pain, itching, and scaling have an important role for improvements in HRQOL and work and daily activity.

Improvements in PASI, patient-reported symptoms, HRQOL, and work and daily activity were greater for those patients on secukinumab vs. ustekinumab.

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Purpose: This study examined direct and indirect (mediated) effects of secukinumab vs. ustekinumab on quality of life, work productivity, and activity impairment based on psoriasis severity and symptoms.

Methods: Analyses were based on data from the CLEAR study. Structural equation modelling (SEM) examined the effects of secukinumab vs. ustekinumab on the Dermatology Life Quality Index (DLQI) and on the Work Productivity and Activity Impairment (WPAI) questionnaire using Psoriasis Area Severity Index (PASI) severity and symptoms (pain, itching, and scaling) as potential mediators. Analyses were conducted primarily for patients achieving PASI 90 response at week 16 (repeated at week 52) and for PASI 50, 75, and 100.

Results: Results at weeks 16 and 52 showed that the effect of treatment on change in DLQI score was mediated by PASI 90 response and by improvements in itching and scaling. Achieving any PASI response as early as week 16 directly resulted in significantly better WPAI scores. At week 52, both PASI response and improvement in scaling directly resulted in significantly better WPAI scores. Pain, itching, and scaling were correlated ($r = 0.51$ to 0.68); improvement in any of these had a significant effect (directly or indirectly) on WPAI. All results favoured secukinumab over ustekinumab.

Conclusion: The results underscore the important role of both PASI response and improved symptoms on improvements in health-related quality of life and work and daily activity in favour of secukinumab vs. ustekinumab.

Keywords: psoriasis; health-related quality of life; work and activity impairment; structural equation modelling

Introduction

The appearance and lifelong, chronic nature of psoriasis result in considerable burden to patients [1] such as sleep impairment [2], depressive symptoms [3,4], negative self-esteem [1], and reduced work productivity. [5,6].

Assessment of psoriasis severity and response to treatment in clinical trials is typically made using the Psoriasis Area Severity Index (PASI) [7]. However, while PASI provides a composite assessment of the signs and extent of psoriasis, it does not yield information about the effect psoriasis has on patients' lives [8]. The Dermatology Life Quality Index (DLQI) is the most commonly used instrument to assess the health-related quality of life (HRQOL) of patients with psoriasis [7,9]. However, increasing evidence confirms only weak to moderate correlations between PASI and DLQI [10,11]. This suggests that factors other than objective disease severity may play a role in patients' evaluations of their HRQOL. Previous research has shown that patients perceive pain, itching, and scaling to be the most troubling aspects of their psoriasis [12,13]. These symptoms are correlated with PASI scores [14] and may affect HRQOL and work and activity impairment.

In a head-to-head clinical trial for the treatment of moderate to severe psoriasis, the CLEAR study, secukinumab has demonstrated sustained greater efficacy versus ustekinumab in clearing skin through week 52; greater improvement in symptoms, HRQOL, work and activity impairment; and a comparable safety profile [15].

The present post hoc analysis from the CLEAR study explored how PASI response and psoriasis symptoms (pain, itching, and scaling) affect HRQOL and work and activity impairment using a sophisticated analytic method, structural

equation modeling (SEM). Further, the analysis explored how these relationships differ between secukinumab and ustekinumab.

Methods

Data

The data for these analyses came from CLEAR, a 52-week, multicenter, randomized, double-blind, head-to-head, parallel-group superiority trial in moderate to severe psoriasis. At baseline, data were available from 336 patients randomized to secukinumab and 339 randomized to ustekinumab. Details of study methods and efficacy/safety results have been previously reported.[15,16].

Measures

Psoriasis Area Severity Index (PASI)

The PASI is a clinician-reported measure evaluating the head, trunk, upper limbs, and lower limbs for the severity and body surface area coverage of erythema, thickening (plaque elevation, induration), and scaling (desquamation) [17-19]. Improvement was assessed by the percentage of reduction in PASI total score from baseline at each time point, with specific thresholds of 50% (PASI 50), 75% (PASI 75), 90% (PASI 90) and 100% (PASI 100) reductions being the main criteria for improvement. The PASI response at weeks 16 and 52 were used for this analysis.

Dermatology Life Quality Index (DLQI)

The DLQI is a 10-item patient-reported measure evaluating the extent to which quality of life (QOL) has been affected by skin problems in the previous week

[20]. Total and subscale scores (Symptoms and Feelings, Daily Activities, Leisure, Work and School, Personal Relationships, and Treatment) are computed. The total DLQI score ranges from 0 (no effect on patient's life) to 30 (extremely large effect on patient's life). The change in DLQI total score at weeks 16 and 52 was used for this analysis.

Work Productivity and Activity Impairment–Psoriasis (WPAI)

The WPAI is a self-administered questionnaire comprised of six questions regarding the effects of psoriasis on the subject's ability to work and perform regular activities and is based on their experiences in the previous 7 days [21]. Scores were calculated for the percent of impairment in daily activities or while working ("presenteeism") and work time missed ("absenteeism"). The WPAI scores from weeks 16 and 52 were used in this analysis.

Patient's assessment of psoriasis-related pain, itching, and scaling

A self-administered, 11-point numeric rating scale (0-10) was used to evaluate the patient's assessment of pain, itching, and scaling over the past 24 hours.

Respondents answered three questions for the assessment of pain, itching, and scaling: "Overall, how severe was your psoriasis-related pain/itching/scaling over the past 24 hours?" A score of 0 represented the absence or null end of the pain, itching, or scale intensity (i.e., no pain, itching, or scaling) and a score of 10 represented the other extreme of pain, itching, or scaling intensity (i.e., pain, itching, or scaling as bad as it could be). Symptom severity scores for psoriasis-related pain, itching, and scaling at weeks 16 and 52 were used in this analysis.

Baseline Covariates

The following covariates, known to potentially drive HRQOL, were also included in the present analyses: age and gender of the patient; body mass index; duration of psoriasis; presence of psoriatic arthritis at baseline; and previous use of biologics/systemics before treatment with secukinumab or ustekinumab in the CLEAR study.

Analyses

The analyses were carried out using SEM, a type of path analysis that involves the use of latent variable (i.e., unobserved variables; also called factors) and manifest variables (i.e., observed variables) to assess the relationships between multiple patient-relevant outcomes simultaneously. [22,23] We used SEM to assess the direct and indirect (i.e., mediated) differential effects of psoriasis treatment (secukinumab vs. ustekinumab), covariates, PASI response, and patient-reported psoriasis-related symptoms (pain, itching, and scaling) on change in DLQI scores from baseline at weeks 16 and 52, and on WPAI scores at weeks 16 and 52. We present PASI 90 results since PASI 90 was the primary efficacy endpoint of the CLEAR study, although the SEM analyses were replicated for PASI 50, 75, and 100 responses.

We hypothesized in the DLQI model that the DLQI Symptoms and Feelings (DLQI-SF) subscale was antecedent to a DLQI Total (Revised) “subscale” combining the remaining five DLQI subscales (Daily Activities, Leisure, Work and School, Personal Relationships, and Treatment subscales; Figure 1). The logic underlying this set of relationships was that changes in PASI response and psoriasis symptoms would first affect the DLQI-SF subscale

(measured by the questions “Over the last week, how itchy, sore, painful, or stinging has your skin been?” and “Over the last week, how embarrassed or self-conscious have you been because of your skin?”); the DLQI-SF subscale would then, in turn, affect the remaining subscales of the DLQI. The five remaining subscales were modelled as alternative measures of a revised latent variable for the DLQI Total.

Three WPAI scores were considered in the SEM model for WPAI: percent of impairment in daily activities, percent of impairment while working (“presenteeism”), and work time missed (“absenteeism”) in the previous 7 days (Figure 2).

Goodness-of-fit tests were used to assess how closely the hypothesized, model-implied relationships fit or represented those in the CLEAR data. In addition to the fit indices, examination of results focused on standardized coefficients (β [i.e., betas] ranging from -1 through 0 to $+1$, where -1 is a perfect inverse relationship between variables, 0 is no relationship, and $+1$ is a perfect positive relationship; standardized coefficients are interpreted in a similar way as correlation coefficients); this approach enabled direct comparison of the strength of relationships between the variables included in the DLQI and the WPAI models.

Results

Baseline comparisons

Baseline characteristics and patient-reported outcome scores for patients in the two treatment arms of the CLEAR study were similar (Table 1). These data have been presented elsewhere [16].

Change in the DLQI score from Baseline to Weeks 16 and 52

Results for the models of the change in DLQI total score from baseline to week 16 and from baseline to week 52 are presented in Figure 3 and Figure 4, respectively. Goodness-of-fit statistics for the DLQI models were all excellent, indicating that the relationships hypothesized in Figure 1 are representative of those in the CLEAR data. Moreover, the fit statistics were much better for the model where DLQI-SF was antecedent to the DLQI Total (Revised) [See Supplemental Information]. This confirms the model hypothesis that if patients feel that their itchy, sore, painful, or stinging skin has improved, or if patients feel less embarrassed or less self-conscious about their skin, they will be more likely to carry out daily activities and personal relationships.

Results of the DLQI model at week 16 showed that the impact of psoriasis treatment on DLQI was not direct but was mediated by both PASI response and psoriasis-related symptoms.

Compared with those treated with ustekinumab, patients treated with secukinumab were significantly more likely to achieve PASI 50/75/90/100 response ($\beta = -0.08, -0.14, -0.22, -0.17$, respectively). Achieving PASI 75 or 90 (but not PASI 50 or PASI 100) significantly improved the DLQI-SF subscale which in turn significantly improved the DLQI Total (Revised) subscale (i.e., the combined total of the other five DLQI subscales). Similarly, improvements in pain, itching, and scaling also significantly improved the DLQI-SF subscale ($\beta = 0.18, 0.41, 0.21$; all $P < 0.05$), which in turn significantly improved the DLQI Total (Revised) subscale ($\beta = 0.50$; $P < 0.05$) in favour of secukinumab over ustekinumab. Improvement in itching had the largest effect on the DLQI-SF subscale and on the DLQI Total (Revised) via the DLQI-SF subscale, although pain and scaling were also significant. The DLQI Total (Revised) subscale was

important to patients, with Leisure, Daily Activities, and Personal Relationships subscales being the most important (i.e., they had the highest standardized coefficients).

Similar results were seen with the DLQI models at Week 52.

WPAI Scores at Week 16 and Week 52

Results for the WPAI models at week 16 and at week 52 are presented in Figure 5 and Figure 6, respectively. Goodness-of-fit statistics for the WPAI models were all excellent, indicating that the hypothesized relationships in Figure 2 reflect the data very well.

Results of the WPAI models at week 16 showed more complex relationships between the different variables than was seen with the DLQI models and that the impact of psoriasis treatment on WPAI was not direct but was mediated by PASI response.

Psoriasis treatment ($\beta = -0.215$) and scaling ($\beta = -0.257$) directly improved PASI 90 response, and patients treated with secukinumab were more likely to achieve PASI 90 response than those treated with ustekinumab. The effects of improvement in psoriasis symptoms on WPAI scores were completely indirect and were mediated by the improvement in PASI response. When scaling improved, pain and itching improved, and this improvement was more likely for those treated with secukinumab vs. ustekinumab. Compared with ustekinumab, treatment with secukinumab indirectly and significantly improved pain and itching ($r \approx 0.07$ and 0.09 , respectively) via improvements in scaling and, in turn, the observed correlations between improvements in scaling and improvements in pain and itching.

Achieving PASI 90 response directly resulted in less WPAI activity impairment ($\beta = -0.215$) and presenteeism ($\beta = -0.2$). Because WPAI activity impairment and presenteeism are significantly correlated with absenteeism in this model, achieving PASI 90 response also resulted in less absenteeism. Given that scaling has a direct effect on PASI response, improvement in scaling indirectly resulted in lower WPAI activity impairment and less presenteeism.

Results of the models at week 16 were similar for all PASI responses.

The results of the WPAI models at week 52 were somewhat different, with both PASI response and symptoms mediating the effects of psoriasis treatment on WPAI scores.

Patients on secukinumab experienced greater improvements in pain, itching, and scaling, and were more likely to achieve PASI 90 response than those on ustekinumab. Improvement in scaling and the achievement of PASI 90 response directly resulted in lower WPAI activity impairment ($\beta = 0.115, -0.223$, respectively), and less presenteeism at week 52 ($\beta = 0.126, -0.236$, respectively). Improvement in scaling and the achievement of PASI 90 response indirectly resulted in less absenteeism at week 52 because absenteeism was correlated with WPAI activity impairment ($r = 0.264$) and presenteeism ($r = 0.305$) in this model. Pain and itching were directly related to psoriasis treatment and were correlated with scaling (which had direct effects on WPAI activity impairment and presenteeism); therefore, pain and itching indirectly resulted in lower WPAI activity impairment, less presenteeism, and less absenteeism at week 52.

Results of the models at week 52 were similar for all PASI responses.

Discussion

This post hoc analysis of the CLEAR 52-week data indicate that the relationships

among psoriasis treatment, PASI response, and psoriasis-related symptoms and HRQOL and work and activity impairment are complex, often involving indirect but significant relationships. The SEM analyses demonstrated that the effect of psoriasis treatment on HRQOL and WPAI are mediated by both PASI response and improvements in patient-reported psoriasis-related pain, itching, and scaling symptoms. Secukinumab showed superior efficacy in clearing skin and relieving symptoms, a finding which resulted in greater positive impact of secukinumab on HRQOL and on WPAI versus ustekinumab.

Clear skin is the ultimate treatment goal and is associated with improved HRQOL. Previously, the effects of improvement in psoriasis symptoms on HRQOL and WPAI were unclear. This analysis provides insight on the importance of relieving bothersome psoriasis symptoms for patients' lives. Griffiths and colleagues [10] reported weak to moderate correlations between DLQI and PASI total scores and noted that changes in QOL do not appear to be captured by PASI or its subscales. Our results demonstrate that, in alignment with this research, factors other than PASI influence HRQOL and, more specifically, that patient-assessed psoriasis symptoms play an important role in affecting patient outcomes. Whereas Leonardi and colleagues [24] focused on the effects of pruritus severity, the present study included three key psoriasis symptoms noted by patients [12,13] and demonstrated their key role in the patient experience with psoriasis.

In 2013, Lewis-Beck and colleagues [25] were first to inform on the presence of direct relationship between psoriasis symptom (pain, itching, and scaling) severity and HRQOL and work and activity impairment among patients with moderate to severe psoriasis using SEM. However the present analyses go

well beyond this research by using a full structural equation model that simultaneously estimates all hypothesized relationships and evaluates the fit of the hypothesized model to the observed data in the CLEAR study without having to use a two-stage analytic approach. Moreover, our models investigate the differential effects of two active treatments for moderate to severe psoriasis and the effects at different time points, which is rarely explored in SEM analyses to our knowledge.

The confirmation of the hypothesis that the Symptoms and Feelings subscale was antecedent to a latent variable (factor) representing the remaining five subscales of the DLQI Total (Revised) was a notable result. The results of the SEM analyses suggested that improving skin clearance and psoriasis symptoms will first improve the patients' experience with itchy, sore, painful, or stinging skin and embarrassment with skin before improving other domains of HRQOL, such as daily activities or personal relationships. Although this seems logical, this measurement model of the DLQI should be explored in future research since it appears to be a novel conception of this measure.

Interestingly, the effects of improvement in psoriasis symptoms on WPAI scores were mediated by improvement in PASI response in the models at week 16, but they directly affected WPAI scores at a later time point (i.e., week 52). This finding may indicate that patients first experience the effects of clear skin on their work and activities followed by the additional effects of improvements in their psoriasis symptoms.

We did not find a relationship between PASI 50/100 responses and changes in the DLQI-SF subscale at week 16, or between PASI 50 response and the DLQI-SF subscale at week 52. For PASI 50 response, this may be caused by

the large skew in the distribution of patients, as almost 95% of patients had attained PASI 50 at both time points. Thus, there was little variability for use as a reliable predictor. It is unclear why we did not find a relationship between PASI 100 response and changes in the DLQI-SF subscale at week 16 whereas a relationship was found at week 52. In contrast, all PASI responses were directly related to WPAI scores at week 16 and week 52. It may be explained by the use of actual scores for WPAI rather than changes in scores from baseline, as with the DLQI and PASI. The rationale behind using actual scores in the SEM rather than the change of scores from baseline was based on the fact that the WPAI collects the work and activity experience of the patient during the past 7 days, excluding the current day. We believe it makes more sense to focus on the WPAI scores at weeks 16 and 52, when the measure has a one-week recall at both time points.

We explored whether a psychological variable such as depression could play a role in explaining some of these relationships following recent findings showing an increased likelihood of depressive symptoms or clinical depression among patients with psoriasis, which may have some etiology in the systemic inflammatory condition that increases risk of brain inflammation [4,26,27]. The only measure of depression/anxiety available from the CLEAR study is the single item from the EuroQol EQ-5D that asks about the extent to which the patient feels anxious or depressed today. As an example, the results of the models of the WPAI that included the EQ-5D anxiety/depression variable showed that improvements in pain and scaling directly resulted in less anxiety/depression, which in turn resulted in less activity impairment and impairment while working (presenteeism). However, an argument could be made that improvements in the WPAI also led to improvement of the EQ-5D anxiety/depression domain. It is not

clear if anxiety or depression is a mediating variable with effects on work and activity impairment or if it is itself an outcome of these QOL domains. Further work is needed to understand the role of anxiety/depression in patients' outcomes.

Some limitations in the current study are worth noting. As with any SEM, there are implied causal relationships with these models and interpretations of many of the paths in these models are that of causal relationships. However, time ordering was built into the DLQI analyses by using PASI score at weeks 16 and 52, and change from baseline in psoriasis symptoms and DLQI scores. For the WPAI analyses, the WPAI scores at weeks 16 or 52 (reflecting the previous 7 days) were used as outcome variables, along with the covariates of PASI responses from baseline to weeks 16 and 52, and change from baseline in psoriasis symptoms. There is nothing inherently wrong with this approach, particularly when the hypothesized relationships are based on sound logic supported by significant empirical results. Nonetheless, firm causal conclusions must be accepted tentatively.

A second possible limitation is that the CLEAR study was a clinical trial, with specific inclusion/exclusion criteria and controls. It would be valuable to know whether these same relationships hold in real-world situations. In addition, analyses were limited to the variables available in the CLEAR study; other relevant variables might play a role in these relationships, but were not available for these analyses.

The DLQI and WPAI were analysed separately (i.e., in separate models) for two reasons: (1) the models became complex analytically because there were many domains of HRQOL outcomes between the two measures, some of which overlapped in content (e.g., DLQI Daily Activities and Work and School with the

WPAI Activity Impairment and Work Impairment); and (2) the combined models would be visually complex and it would be difficult to see individual paths. Thus, we feel the approach used in this analysis provides the clearest presentation of the complex relationships and yields the same conclusions.

The SEM analyses utilized here represent a powerful and informative analytic method that has helped us obtain a detailed understanding of the differential direct and indirect effects of secukinumab versus ustekinumab on multiple patient-relevant outcomes simultaneously. These analyses underscore the important role of both clear skin and improved psoriasis-related symptoms in affecting the lives of patients with moderate to severe psoriasis; these findings also produce explanatory insights into the greater impact of secukinumab treatment versus ustekinumab in improving patient-reported outcomes.

Acknowledgments

The authors would like to thank the patients and the investigators who participated in the study as well as Lori McLeod, PhD, and Margaret Mordin, MS, for reviewing the manuscript. Yang Zhao was an employee of Novartis Pharmaceuticals Corporation when this research was conducted.

Conflict(s) of Interest

DES, BS and KH are employed by RTI Health Solutions. CEMG is a consultant and has received grants from Novartis; has been a paid advisor and/or in receipt of research grants from AbbVie, Actelion, BMS, GSK, Galderma, Janssen, Leo Pharma, MSD, Pfizer, Novartis, Sandoz, Eli Lilly, Regeneron, Roche, L'Oreal, DSM, Clarins, Walgreens Boots Alliance and UCB Pharma. AYF is joint copyright owner of the DLQI: Cardiff University and AYF receive royalties. AYF has received honoraria from Novartis for advisory board membership, and from Galderma, Napp, Sanofi and Eli Lilly. IG and AG are employed by Novartis Pharma, AG, and Novartis Pharmaceuticals Corporation, respectively. YZ is employed by Sun Pharma, but was employed by Novartis Pharmaceuticals Corporation at the time this research was conducted. LP has received grants or honoraria from Abbvie, Almirall Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, and Sandoz.

References

1. Augustin M, Radtke MA. Quality of life in psoriasis patients. *Expert Rev Pharmacoecon Outcomes Res.* 2014;14:559–568.

2. Thaçi D, Galimberti R, Amaya-Guerra M, et al. Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. *J Eur Acad Dermatol Venereol*. 2014;28(7):900–906.
3. Schmitt J, Wozel G, Garzarolli M, et al. Effectiveness of interdisciplinary vs. dermatological care of moderate-to-severe psoriasis: a pragmatic randomised controlled trial. *Acta Derm Venereol*. 2014;94(2):192–197.
4. Patel N, Nadkarni A, Cardwell LA, et al. Psoriasis, depression, and inflammatory overlap: a review. *Am J Clin Dermatol*. 2017 [cited 2017 June 26]. DOI: 10.1007/s40257-017-0279-8
5. Armstrong AW, Schupp C, Wu J, et al. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. *PLoS One*. 2012;7(12):e52935.
6. Wu Y, Mills D, Bala M. Impact of psoriasis on patients' work and productivity: a retrospective, matched case-control analysis. *Am J Clin Dermatol*. 2009;10(6):407–410.
7. Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. *J Eur Acad Dermatol Venereol*. 2014;28(3):333–337.
8. Puig L. PASI90 response: the new standard in therapeutic efficacy for psoriasis. *J Eur Acad Dermatol Venereol*. 2015;29(4):645–648.
9. Ali FM, Cueva AC, Vyas J, et al. A systematic review of the use of quality of life instruments in randomized controlled trials of psoriasis. *Br J Dermatol* 2017;176(3):577–593.
10. Griffiths CE, Sterry W, Brock F, et al. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept. *Br J Dermatol*. 2015;172(1):230–238.
11. Kitchen H, Cordingley L, Young H, et al. Patient-reported outcome measures in psoriasis: the good, the bad and the missing! *Br J Dermatol*. 2015;172(5):1210–1221.

12. Lebwohl M, Swensen AR, Nyirady J, et al. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. *Int J Dermatol*. 2014;53(6):714–722.
13. Strober B, Sigurgeirsson B, Popp G, et al. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials. *Int J Dermatol*. 2016;55(4):401–407.
14. Gottlieb AB, Strober B, Lebwohl M, et al. Greater efficacy with secukinumab treatment is associated with greater psoriasis symptom relief: results from secukinumab clinical trial data. *J Psoriasis Psoriatic Arthritis*. 2017 [cited 2017 June 26]. URL: <https://www.psoriasis.org/content/greater-efficacy-secukinumab-treatment-associated-greater-psoriasis-symptom-relief-results>
15. Blauvelt A, Reich K, Tsai TF, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. *J Am Acad Dermatol*. 2017;76:60–69.
16. Thaci D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. *J Am Acad Dermatol*. 2015;73:400–409.
17. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica*. 1978;157(4):238–244.
18. Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. *J Dermatolog Treat*. 2003;14(3):158–165.
19. Gottlieb AB, Griffiths CE, Ho VC, et al; Multi-Centre Investigator Group. Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. *Br J Dermatol*. 2005;152(6):1219–1227.
20. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210–216.

21. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. *Pharmacoeconomics*. 1993;4(5):353–365.
22. Kline RB. *Principals and practice of structural equation modeling*. New York (NY): Guilford; 2011.
23. Tomarken AJ, Waller NG. Structural equation modeling: strengths, limitations, and misconceptions. *Annu Rev Clin Psychol*. 2005;1:31–65.
24. Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. *J Eur Acad Dermatol Venereol*. 2017 [cited 2017 June 26]. DOI: 10.1111/jdv.14211
25. Lewis-Beck C, Abouzaid S, Xie L, et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. *Patient Prefer Adherence*. 2013;7:199–205.
26. Hunter HJ, Hinz R, Gerhard A, et al. Brain inflammation and psoriasis: a [(11) C]-(R)-PK11195 positron emission tomography study. *Br J Dermatol*. 2016;175(5):1082–1084.
27. Dowlatshahi EA, Wakkee M, Arends LR, et al. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. *J Invest Dermatol*. 2014;134:1542–1551.

Tables

Table 1. Baseline Demographics and PRO Scores of the Two Treatment Groups


	Secukinumab	Ustekinumab
	(N = 336)	(N = 339)
Age, years, mean (SD)	45.2 (13.96)	44.6 (13.67)
Male, n (%)	229 (68.0)	252 (74.3)
Weight (kg)	87.4 (19.95)	87.2 (22.11)
Currently employed at baseline, n (%)	228 (67.7)	225 (66.4)
Patient-reported outcomes		
DLQI total score	13.4 (7.63)	13.2 (7.57)
WPAI: Absenteeism	5.39 (14.986)	5.96 (15.672)
WPAI: Presenteeism	27.31 (26.095)	26.17 (24.304)
WPAI: Activity impairment	36.87(29.942)	35.83 (29.186)

DLQI = Dermatology Life Quality Index; PRO = patient-reported outcome;

SD = standard deviation; WPAI = Work Productivity and Activity Impairment


Legends and Figures

Figure 1. Hypothesized Structural Equation Model of Predictors of the DLQI




BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area Severity Index.

Figure 2. Hypothesized Structural Equation Model of Predictors of the WPAI




BMI = body mass index; PASI = Psoriasis Area Severity Index; WPAI = Work Productivity and Activity Impairment.

Figure 3. PASI 90, Changes in Itching, Pain, and Scaling with Changes in DLQI at Week 16



BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area Severity Index; PSA = psoriatic arthritis; Tx = treatment.


Figure 4. PASI 90, Changes in Itching, Pain, and Scaling with Changes in DLQI at Week 52



BMI = body mass index; DLQI = Dermatology Life Quality Index; PASI = Psoriasis Area and Severity Index; PSA = psoriatic arthritis; Tx = treatment.

Note: For both Figures 3 and 4, only paths significant at $P \leq 0.05$ are shown. Variables in squares = observed variables; variable in a circle = latent variable. Direct effects are depicted as an arrow emanating from an independent variable leading and pointing to a dependent variable (outcome). An indirect effect is depicted as a mediating variable having an arrow pointing to it from an independent variable but also pointing to yet another dependent variable.

Figure 5. PASI 90 Changes in Itching, Pain, and Scaling With WPAI Activity Impairment, Work Impairment, and Work Time Missed at Week 16



BMI = body mass index; PASI = Psoriasis Area and Severity Index; PSA = psoriatic arthritis; Tx = treatment; WPAI = Work Productivity and Activity Impairment.

